← Leaderboards
Jamie Berta Spangler
Johns Hopkins University
$2,924,176
Attributed
$3,843,886
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,843,886 · 5
By mechanism
R01$2,436,523 · 2
R21$845,523 · 2
P41$561,840 · 1
Top collaborators
- Warren L Grayson2 shared
- Kevin J Yarema2 shared
- Ype Peter De Jong1 shared
- Roland W. Herzog1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Richard A Cone$17,702,134
- Hai-Quan Mao$12,355,305
- Michael J Betenbaugh$7,039,139
- Warren L Grayson$2,912,603
- Diane E Griffin$24,000,430
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsTechnologyEngineeringDesignSafetyImmune ActivationIn VivoAnimal ModelRegulatory T-LymphocyteSignal TransductionInterleukin-2AntibodiesResponseProtein EngineeringBindingInterestEffector CellCytokineImmuneImmune ResponseMouse ModelAntigensProteinsAntigen-Presenting Cells
Grant awards (11)
Enhancing immune regulation in gene therapy for hemophilia$745,423
R01 · FY2025 · HL
TR&D Project 3$290,858
P41 · FY2025 · EB · contact PI
TR&D Project 3$270,982
P41 · FY2024 · EB · contact PI
Immunoengineered nanotechnology for targeted expansion of regulatory T cells$410,855
R01 · FY2023 · EB · contact PI
Engineered osteogenic growth factors for targeted stimulation of bone regeneration$238,067
R21 · FY2023 · DE · contact PI
Immunoengineered nanotechnology for targeted expansion of regulatory T cells$420,417
R01 · FY2022 · EB · contact PI
Engineered osteogenic growth factors for targeted stimulation of bone regeneration$197,277
R21 · FY2022 · DE · contact PI
Immunoengineered nanotechnology for targeted expansion of regulatory T cells$421,107
R01 · FY2021 · EB · contact PI
OPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERING$187,064
R21 · FY2021 · CA
Immunoengineered nanotechnology for targeted expansion of regulatory T cells$438,721
R01 · FY2020 · EB · contact PI
OPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERING$223,115
R21 · FY2020 · CA